irreversible alpha selective PI3K inhibitors (Pathway Therapeutics)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nameirreversible alpha selective PI3K inhibitors (Pathway Therapeutics)
Drug Alias Nameirreversible alpha selective phosphatidylinositol-3-kinase inhibitors (Pathway Therapeutics/University of Auckland)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitors
TargetsPhosphatidylinositol 3 kinase alpha
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Auckland
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of AucklandPathway Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A